The FDA has approved 2 new acute myeloid leukemia (AML) treatments: one for older adults who cannot undergo intensive chemotherapy and another for patients with a certain genetic mutation.
Glasdegib tablets are indicated for use in combination with a low dose of the chemotherapy medication cytarabine in adults aged 75 years or older with newly diagnosed AML. The combination is intended to help older adults who can’t tolerate intensive chemotherapy’s toxicities, said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence.
Voelker R. New Acute Myeloid Leukemia Therapy. JAMA. 2019;321(1):23. doi:10.1001/jama.2018.20416
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: